| 摘要 |
The present invention relates to the use of an enantiomerically pure R-NSAID for the manufacture of a medicament for inflammation in an animal, wherein the medicament provides a dose of more than 2.5 milligrams per kilogram of the animal's body weight and wherein the R- NSAID is R-flurbiprofen. The anti-inflammatory action of R-NSAIDs is due to their ability to interfer e with the biosynthesis of COX-2 by inhibiting COX-2 mRNA synthesis, rather than by just blocking the action of the enzyme itself. In order to effect the inhibition of COX-2 mRNA synthesis, the R-NSA ID must be present at relatively high doses. Because the R-NSAID is selective in its action, that is it does not inhibit either COX-1 mRNA synthesis or the COX-1 enzyme itself, it can be administered in t he required high doses because the tissue protective effects of prostaglandins made through t he COX-1 pathway are not interfered with.
|
